浙江医学2011，Vol.33Issue(12)：1769-1771,1774,4.
西妥昔单抗联合放化疗治疗晚期头颈部恶性肿瘤
Cetuximab combined with chemotherapy or radiotherapy in treatment of advanced or recurrent head and neck cancer
包婺安 1胡福军 1李斌 1姜锋 1秦卫丰 1冯星来 1陈晓钟1
作者信息
- 1. 310022,杭州,浙江省肿瘤医院头颈放疗科
- 折叠
摘要
Abstract
To evaluate the safety, tolerability and efficacy of cetuximab combined with chemotherapy or radio-therapy in treatment of advanced or recurrent head and neck cancer.MethodsTwenty six patients with advanced or recurrenthead and neck cancer were treated with cetuximab in combination with radiotherapy and/or chemotherapy from Nov 2007 to May 2010. The efficacy and adverse events of therapy were assessed.ResultsOut of 26 cases, 17 achieved CR, 4 achieved PR, 3achieved SD, 1 had PD and 1 patient could not be evaluated. The loading dose of cetuximab was 400mg/m2, followed by weekly infusions of 250mg/m2. All patients were followed up for a median of 11 months. During the follow-up 5 patients were found to have PD, the time of tumor progression (TTP) was 4 to 22 months with a median of 7 months; the survival time was 4 to 33 months with a median of 11 months. The most common adverse events were skin reactions, especially acne-like rash. The radiation mu-cositis during the combined treatment was the mainly RT/CT side effects and well-tolerated.ConclusionCetuximab can enhancethe short-term efficacy of chemo/radiotherapy without increasing toxicities associated with chemo/radiotherapy, except coexisting acne-like rash.关键词
头颈部恶性肿瘤/西妥昔单抗/放射治疗/化学治疗Key words
Head and neck cancer/ Cetuximab / Radiotherapy/ Chemotherapy引用本文复制引用
包婺安,胡福军,李斌,姜锋,秦卫丰,冯星来,陈晓钟..西妥昔单抗联合放化疗治疗晚期头颈部恶性肿瘤[J].浙江医学,2011,33(12):1769-1771,1774,4.
